Epidemiological Study on Invasive Bacterial Diseases

Condition(s) studied

Investigational drug(s) / intervention(s)

assessment of pathogens in blood specimens: Molecular diagnosis of Invasive bacterial diseases due to Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae

Study summary

Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), and Haemophilus influenzae (hemophilus) are among the main bacteria responsible for invasive bacterial diseases (MBIs) that result in severe clinical pictures also characterized by a high frequency of serious complications. Surveillance of infections caused by these pathogens and their distribution by serotypes/serogroups is essential to guide public health interventions, assess epidemiologic trends, monitor any secondary cases, estimate the proportion of preventable cases, identify any vaccine failures, and evaluate the impact of vaccine strategies.The present study aims to study the epidemiology of invasive bacterial diseases, characterize the circulating strains also in order to plan treatment and prevention strategies.

Eligibility

Primary outcome measure(s)

• Incidence rate of Infective Bacterial Diseases from Streptococcus pneumoniae (pneumococcus) during the study period in pediatric age. — Through study completion, an average of 1 year
  Monitor the trend of Infective Bacterial Diseases cases Streptococcus pneumoniae (pneumococcus) in Italy, during pediatric age.
• Incidence rate of of Infective Bacterial Diseases cases from Neisseria meningitidis during the study period in pediatric age. — Through study completion, an average of 1 year
  Frequencies of Infective Bacterial Diseases cases from Neisseria meningitidis in Italy (meningococcus)
• Incidence rate of Infective Bacterial Diseases cases from Haemophilus influenzae during the study period in pediatric age. — Through study completion, an average of 1 year
  Frequencies of Infective Bacterial Diseases cases from Haemophilus influenzae (hemophilus) in Italy

Trial sites (38)

More Meyer Children's Hospital IRCCS trials in Italy